Companies › 35Pharma Inc., a GSK company
1 active drug program in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HS235 Activin signaling inhibitor | – | Phase 1 | Pulmonary Arterial Hypertension; Pulmonary Hypertension | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07143448 | HS235 | Phase 1 | Pulmonary Arterial Hypertension | Cardiovascular | Mar 2028 |
| NCT07123779 | HS235 | Phase 1 | Pulmonary Hypertension | Cardiovascular | Jan 2029 |
Cash of 3.4bn GBP on 2025-12-31; operating cash flow positive
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.